Novel 3D Magnetic Resonance Elastography for the Noninvasive Diagnosis of Advanced Fibrosis in NAFLD: A Prospective Study

American Journal of Gastroenterology

Volumn 111, Issue 7, 2016, Pages 986-994

  Loomba, Rohit ^a,b   Cui, Jeffrey ^a   Wolfson, Tanya ^b   Haufe, William ^b   Hooker, Jonathan ^b   Szeverenyi, Nikolaus ^b   Ang, Brandon ^a   Bhatt, Archana ^a   Wang, Kang ^b   Aryafar, Hamed ^b   Behling, Cindy ^c   Valasek, Mark A ^b   Lin, Grace Y ^b   Gamst, Anthony ^b   Brenner, David A ^a   Yin, Meng ^d   Glaser, Kevin J ^d   Ehman, Richard L ^d   Sirlin, Claude B ^b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Sharp Health System   (United States)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ELASTOGRAPHY; FEMALE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAGNETIC RESONANCE ELASTOGRAPHY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; THREE DIMENSIONAL IMAGING; BIOPSY; CALIFORNIA; COMPARATIVE EFFECTIVENESS; COMPARATIVE STUDY; COMPLICATION; DIAGNOSTIC IMAGING; DIMENSIONAL MEASUREMENT ACCURACY; LIVER; LIVER CIRRHOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PATIENT ACUITY; PROCEDURES;

ADULT; BIOPSY; CALIFORNIA; COMPARATIVE EFFECTIVENESS RESEARCH; CROSS-SECTIONAL STUDIES; DIMENSIONAL MEASUREMENT ACCURACY; ELASTICITY IMAGING TECHNIQUES; FEMALE; HUMANS; IMAGING, THREE-DIMENSIONAL; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PATIENT ACUITY; PROSPECTIVE STUDIES;

EID: 84973289676     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2016.65     Document Type: Article

References (48)

1. Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol 2012; 107: 811-26.
2. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013; 10: 686-90.
3. Vernon G, Baranova A, Younossi ZM. Systemic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-85.
4. Williamson RM, Price JF, Glancy S et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care 2011; 34: 1139-44.
5. Loomba R, Abraham M, Unalp A et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 2012; 56: 943-51.
6. Arulanandan A, Ang B, Bettencourt R et al. Association between quantity of liver fat and cardiovascular risk in patients with nonalcoholic fatty liver disease independent of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2015; 13: 1513-20.e1.
7. Williams CD, Stengel J, Asike MI et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140: 124-31.
8. Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-95.
9. Lazo M, Hernaez R, Bonekamp S et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ 2011; 343: d6891.
10. Adams LA, Lymp JF, St. Sauver J et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-21.
11. Ekstedt M, Franzen LE, Mathiesen UL et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-73.
12. Guzman G, Brunt EM, Petrovic LM et al. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? Arch Pathol Lab Med 2008; 132: 1761-6.
13. Matteoni CA, Younossi ZM, Gramlich T et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9.
14. Ratziu V. Charlotte F, Heurtier A et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898-906.
15. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000; 32: 477-81.
16. Cusi K, Chang Z, Harrison S et al. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with nonalcoholic fatty liver disease (NAFLD). J Hepatol 2014; 60: 167-74.
17. Angulo P, Hui JM, Marchesini G et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-54.
18. Sterling RK, Lissen E, Clumeck N et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-25.
19. Guha IN, Parkes J, Roderick P et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008; 47: 455-60.
20. Shah AG, Lydecker A, Murray K et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: 1104-12.
21. McPherson S, Stewart SF, Henderson E et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with nonalcoholic fatty liver disease. Gut 2010; 59: 1265-9.
22. Palmeri ML, Wang MH, Rouze NC et al. Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. J Hepatol 2011; 55: 666-72.
23. Friedrich-Rust M, Nierhoff J, Lupsor M et al. Performance of Acoustic Radiation Force Impulse imaging for the staging of liver fibrosis: a pooled meta-analysis. J Viral Hepat 2012; 19: e212-e219.
24. Myers RP, Pomier-Layrargues G, Kirsch R et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012; 55: 199-208.
25. Wong VW, Vergniol J, Wong GL et al. Liver stiffness measurement using XL probe in patients with non-alcoholic fatty liver disease. Am J Gastroenterol 2012; 107: 1862-71.
26. Huwart L, Sempoux C, Vicaut E et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 2008; 135: 32-40.
27. Kim D, Kim WR, Talwalkar JA et al. Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography. Radiology 2013; 268: 411-9.
28. Loomba R, Wolfson T, Ang B et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology 2014; 60: 1920-8.
29. Le T-A, Chen J, Changchien C et al. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology 2012; 56: 922-32.
30. Loomba R, Sirlin CB, Ang B et al. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel MRI and MRE in a randomized trial (MOZART Trial). Hepatology 2015; 61: 1239-50.
31. Neuschwander-Tetri BA, Loomba R, Sanyal AJ et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicenter, randomized, placebo-controlled trial. Lancet 2015; 385: 956-65.
32. Patel NS, Doycheva I, Peterson MR et al. Effect of weight loss on magnetic resonance imaging estimation of liver fat and volume in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2015; 13: 561-8.
33. Zarrinpar A, Gupta S, Maurya MR et al. Serum microRNAs explain discordance of non-alcoholic fatty liver disease in monozygotic and dizygotic twins: a prospective study. Gut 2015; doi:10.1136/gutjnl-2015-309456.
34. Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
35. Yin M, Talwalkar JA, Glaser KJ et al. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol 2007; 5: 1207-1213.e2.
36. Chen J, Talwalkar JA, Yin M et al. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology 2011; 259: 749-56.
37. Venkatesh SK, Yin M, Ehman RL. Magnetic resonance elastography of liver: technique, analysis, and clinical applications. J Magn Reson Imaging 2013; 37: 544-55.
38. Loomba R, Schork N, Chen CH et al. Heritability of hepatic fibrosis and steatosis based on a prospective twin study. Gastroenterology 2015; 149: 1784-93.
39. Oliphant TE, Manduca A, Ehman RL et al. Complex-valued stiffness reconstruction for magnetic resonance elastography by algebraic inversion of the differential equation. Magn Reson Med 2001; 45: 299-310.
40. Permutt Z, Le T-A, Peterson MR et al. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease-MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther 2012; 36: 22-9.
41. Noureddin M, Lam J, Peterson MR et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology 2013; 58: 1930-40.
42. Wai C-T, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
43. DeLong ER, DeLong EM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-45.
44. Lin SC, Heba E, Wolfson T et al. Noninvasive diagnosis of nonalcoholic fatty liver disease and quantification of liver fat using a new quantitative ultrasound technique. Clin Gastroenterol Hepatol 2015; 13: 1337-1345.e6.
45. Castera L, Vilgrain V, Angulo P. Noninvasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol 2013; 10: 666-75.
46. Berzigotti A, Castera L. Update on ultrasound imaging of liver fibrosis. J Hepatol 2013; 59: 180-2.
47. Dill T. Contraindications to magnetic resonance imaging: non-invasive imaging. Heart 2008; 94: 943-8.
48. Cui J, Ang B, Haufe W. Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study. Aliment Pharmacol Ther 2015; 41: 1271-80.